Please login to the form below

Not currently logged in
Email:
Password:

EMEA recommends generic copies of Roche's CellCept

The EMEA recommends approval of Teva's generic versions of Swiss pharmaceutical company Roche's anti-rejection drug CellCept

A Reuter's report has revealed that the European Medicines Agency (EMEA) has recommended approval of Teva Pharmaceutical's generic versions of Swiss pharmaceutical company Roche's anti-rejection drug CellCept (mycophenolate mofetil).

The generic copies of CellCept, Myfenax and mycophenolate mofetil Teva, are indicated for preventing acute transplant rejection in patients receiving kidney, heart, or liver transplants.

Roche's CellCept was approved by the EMEA in 1996. The Reuters report noted that marketing recommendation by the EMEA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the EU Commission within a few months.

Pacific Growth Equities analysts have projected flat CellCept sales for Roche until the US patent expiration in 2009. They also noted CellCept's failure in a phase III clinical trial for lupus nephritis. The 370-patient, 24-week, randomised, open-label study failed to prove that CellCept was superior to intravenous cyclophosphamide (IVC).

The analysts added that US payers might push back on the USD 7,000 per year price of CellCept, compared with the USD 1,000 per year price of IVC.

17th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics